Cargando…

Case Report: A rare case of recurrent ascites after anti-Claudin18.2 antibody therapy for metastatic gastric cancer while responding sustainingly

BACKGROUND: Gastric cancer remains one of the deadliest malignancies in the world, thus urgently requiring effective and safe therapeutics. Claudin18.2 is a member of the tight junction protein family specifically expressed in gastric cancer cells. Monoclonal antibodies targeting Claudin18.2 have be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jinlu, Jiang, Dan, Lei, Qingqiang, Zhu, Qing, Zhu, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482433/ https://www.ncbi.nlm.nih.gov/pubmed/37681021 http://dx.doi.org/10.3389/fonc.2023.1211668

Ejemplares similares

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
por: Arnold, A., et al.
Publicado: (2020)

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
por: Zhang, Jianwei, et al.
Publicado: (2020)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
por: Xu, Bo, et al.
Publicado: (2022)

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
por: Singh, Prabhsimranjot, et al.
Publicado: (2017)

Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
por: Ungureanu, Bogdan Silviu, et al.
Publicado: (2021)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
por: Kim, Hyung-Don, et al.
Publicado: (2023)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
por: Cao, Weijie, et al.
Publicado: (2022)

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
por: Bähr-Mahmud, Hayat, et al.
Publicado: (2023)

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
por: Rohde, Christoph, et al.
Publicado: (2019)

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
por: Hong, Jung Yong, et al.
Publicado: (2020)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)

Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours
por: Wang, Fujun, et al.
Publicado: (2023)

Development and comparison of (68)Ga/(18)F/(64)Cu-labeled nanobody tracers probing Claudin18.2
por: Wei, Weijun, et al.
Publicado: (2022)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
por: Qi, Changsong, et al.
Publicado: (2022)

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
por: Zhong, Weixiang, et al.
Publicado: (2022)

Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
por: Kim, Seo Ree, et al.
Publicado: (2020)

Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
por: Dottermusch, Matthias, et al.
Publicado: (2019)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
por: Liu, Shiyu, et al.
Publicado: (2023)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
por: Shi, Hongtai, et al.
Publicado: (2023)

FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
por: Liu, Yifan, et al.
Publicado: (2023)

Autoimmune Ascites Responding to Mycophenolate Mofetil: A Case Report
por: Simonetto, Douglas A., et al.
Publicado: (2018)

An Obscure Case of Recurrent Ascites and Edema
por: Blumer, George, et al.
Publicado: (1929)

MiRNA-182-5p aggravates experimental ulcerative colitis via sponging Claudin-2
por: Tang, Siwen, et al.
Publicado: (2021)

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
por: Wang, Canming, et al.
Publicado: (2023)

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models
por: Riad, Sarah E., et al.
Publicado: (2018)

Clinicopathological significance of claudin-4 in gastric carcinoma
por: Zhu, Jin-Liang, et al.
Publicado: (2013)

Claudins and Gastric Cancer: An Overview
por: Hashimoto, Itaru, et al.
Publicado: (2022)

CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

Immunoexpression of Claudin 4 in Gastric Adenocarcinomas
por: CREȚU, OANA IULIA, et al.
Publicado: (2022)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8skne8kq8omv1bgav6ona6jamj